Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-22
2011-03-22
Desai, Rita J (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S318000
Reexamination Certificate
active
07910741
ABSTRACT:
A compound represented by the following general formula (I), its salt, solvates thereof or prodrugs thereof:(wherein each symbol is as defined in the description.) The compounds represented by the general formula (I) are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.
REFERENCES:
patent: 3375256 (1968-03-01), Bach et al.
patent: 5169855 (1992-12-01), Cain et al.
patent: 5486534 (1996-01-01), Lee et al.
patent: 6096780 (2000-08-01), Shiraishi et al.
patent: 6268354 (2001-07-01), Nishimura et al.
patent: 6376536 (2002-04-01), Shiraishi et al.
patent: 6515027 (2003-02-01), Bondinell et al.
patent: 6720321 (2004-04-01), Cirillo et al.
patent: 6765009 (2004-07-01), Francesco et al.
patent: 6894063 (2005-05-01), Greenlee et al.
patent: 6903085 (2005-06-01), Thom et al.
patent: 7053090 (2006-05-01), Habashita et al.
patent: 7071213 (2006-07-01), Friary et al.
patent: 7247725 (2007-07-01), Butora et al.
patent: 2002/0165223 (2002-11-01), Greenlee et al.
patent: 2003/0069276 (2003-04-01), Edlin et al.
patent: 2003/0083333 (2003-05-01), Cirillo et al.
patent: 2003/0100608 (2003-05-01), Cirillo et al.
patent: 2003/0114517 (2003-06-01), Greenlee et al.
patent: 2003/0195192 (2003-10-01), Haviv et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0010013 (2004-01-01), Friary et al.
patent: 2004/0082584 (2004-04-01), Habashita et al.
patent: 2004/0158067 (2004-08-01), Hutchison et al.
patent: 2005/0038100 (2005-02-01), Greenlee et al.
patent: 2005/0215557 (2005-09-01), Habashita et al.
patent: 2005/0250792 (2005-11-01), Thom et al.
patent: 2005/0261325 (2005-11-01), Butora et al.
patent: 2005/0267114 (2005-12-01), Takaoka et al.
patent: 2005/0282861 (2005-12-01), Friary et al.
patent: 2006/0178397 (2006-08-01), MacDonald et al.
patent: 2006/0178399 (2006-08-01), Nishizawa et al.
patent: 2007/0066624 (2007-03-01), Zhou et al.
patent: 2008/0057074 (2008-03-01), Takaoka et al.
patent: 2009/0131403 (2009-05-01), Kusuda et al.
patent: 0449187 (1991-10-01), None
patent: 0748805 (1996-12-01), None
patent: 1020445 (2000-07-01), None
patent: 1 236 726 (2002-09-01), None
patent: 1378510 (2004-01-01), None
patent: 1422219 (2004-05-01), None
patent: 1541574 (2005-06-01), None
patent: 1604981 (2005-12-01), None
patent: 1790637 (2007-05-01), None
patent: 4-356462 (1992-12-01), None
patent: 2000-128782 (2000-05-01), None
patent: 2001-518505 (2001-10-01), None
patent: 2004-528318 (2004-09-01), None
patent: 2004-534787 (2004-11-01), None
patent: 2007-63268 (2007-03-01), None
patent: 2199535 (2003-02-01), None
patent: 96/10012 (1996-04-01), None
patent: 97/36903 (1997-10-01), None
patent: 99-01127 (1999-01-01), None
patent: 9917773 (1999-04-01), None
patent: WO 99/31062 (1999-06-01), None
patent: 99-32100 (1999-07-01), None
patent: 0224636 (2002-03-01), None
patent: 02053560 (2002-07-01), None
patent: 02/074758 (2002-09-01), None
patent: 02/074770 (2002-09-01), None
patent: 02/079186 (2002-10-01), None
patent: 02/083628 (2002-10-01), None
patent: 02/098869 (2002-12-01), None
patent: 03/020703 (2003-03-01), None
patent: 03037271 (2003-05-01), None
patent: 03/066592 (2003-08-01), None
patent: 03/104230 (2003-12-01), None
patent: WO 2004/026873 (2004-04-01), None
patent: WO 2004/043925 (2004-05-01), None
patent: 2004/046110 (2004-06-01), None
patent: 2004/080966 (2004-09-01), None
patent: 2004-096131 (2004-11-01), None
patent: 2006/030925 (2006-03-01), None
patent: 2007/022371 (2007-02-01), None
patent: 2007/105637 (2007-09-01), None
http://wordnetweb.princeton.edu/perl/webwn?s=medicament.—Definition of the term “medicament”, 2010.
Office Action, App. No. 2004800130029, Chinese Patent Office, May 11, 2007.
Subhash P. Khanapure et al., “Synthesis and Structure-Activity Relationship of Novel, Highly Potent Metharyl and Methcycloalkyl Cyclooxgenase-2 (COX-2) Selective Inhibitors”, Journal of Medicinal Chemistry, 2003, pp. 5484-5504, vol. 46, No. 25, American Chemical Society.
Daniel Ledniger et al., “Mammalian Antifertility Agents. IV. Basic 3,4-Dihydronaphthalenes and 1,2,3,4-Tetrahydro-1-Naphthols”,1967, pp. 79-84, vol. 10, Journal Medicinal Chemistry.
European Patent Office Communication re: Observations by a Third Party for EP057858086 dated May 13, 2008.
Millet et al.,“Potent and Selective Farnesy/Transferase Inhibitors”, J.Med. Chem., 2004, vol. 47, pp. 6812-6820.
International Search Report dated Jun. 1, 2004.
Mashkovskiy, M.D., “Medicinal Drugs”, 2001, p. 11, vol. 1, 14th Ed., S.B. Divov, Moscow.
Russian Office Action dated Jul. 9, 2009 in Russian Application No. 2007113814.
Office Action issued in counterpart European Patent Application No. 04720257.7 dated Dec. 15, 2009.
Singaporean Office Action dated Jan. 19, 2010 in Singapore Application No. 200806533-6.
Extended European Search Report dated Feb. 18, 2010 in European Application No. 05785808.6-1521.
Chinese Office Action dated Mar. 10, 2010 in Chinese application No. 200810133648.0.
Japanese Office Action issued May 18, 2010 in corresponding Japanese Application No. 2005-503613.
New Zealand Office Action dated Apr. 8, 2010 in New Zealand application No. 571019.
McClellan William, et al., “Preparation of N-arylcarbonyl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-XI and Bcl-2 as promoters of apoptosis” XP002503148, Database (Online) Chemical Abstract Service, pp. 1-3, 2002.
Supplementary European Search Report dated Nov. 26, 2008.
Office Action issued on Apr. 14, 2010 in counterpart Russian Application No. 2007113814.
Vietnamese Office Action issued Jun. 10, 2010 in Vietnamese application No. 1-2005-01233.
Office Action issued May 11, 2010 in counterpart Chinese Application No. 200810133649.5.
European Search Report issued on Oct. 19, 2010 in counterpart European application No. 07 738 169.7 of the co-pending U.S. Appl. No. 12/282,464.
Office Action issued on Sep. 10, 2010 in counterpart European application No. 04 720 257.7.
Office Action issued on Sep. 23, 2010 in counterpart Norwegian application No. 2005 4244.
Office Action issued on Sep. 28, 2010 in counterpart European application No. 05 785 808.6 of co-pending U.S. Appl. No. 11/662,639.
Shomir Ghosh et. al.: “Design, Synthesis, and Progress toward Optimization of Potent Small Molecule Antagonists of CC Chemokine Receptor 8 (CCR8)”, Journal of Medicinal Chemistry, vol. 49. No. 9, May 4, 2006; pp. 2669-2672.
The Second Office Action dated Oct. 12, 2010 from The Patent Office of the People's Republic of China issued in co-pending U.S. Appl. No. 11/662,639 of counterpart Chinese application No. 200580038925.4.
Office Action dated Oct. 19, 2010 from the Canadian Intellectual Property Office issued in counterpart Canadian application No. 2,517,888.
Australian Office Action issued in Application No. 2005-283326; dated Nov. 9, 2010.
Nishizawa Rena
Shibayama Shiro
Takaoka Yoshikazu
Desai Rita J
Mabry John
Ono Pharmaceutical Co. Ltd.
Sughrue & Mion, PLLC
LandOfFree
Nitrogen-containing heterocyclic derivatives and drugs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrogen-containing heterocyclic derivatives and drugs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogen-containing heterocyclic derivatives and drugs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2782337